PSMB11: A Potential Drug Target and Biomarker for Prostate Cancer

Target Name: PSMB11

NCBI ID: G122706

PSMB11

PSMB11: A Potential Drug Target and Biomarker for Prostate Cancer

Introduction

Prostate cancer is a leading cause of cancer-related deaths worldwide, with an estimated 97,000 new cases and 6,500 deaths in the United States in 2020. The development of new treatments and biomarkers for prostate cancer is crucial for improving treatment outcomes and increasing survival rates. One promising candidate for drug targeting and biomarker research is PSMB11 (Prosperinib), a small molecule inhibitor of the B-cell maturation antigen (BMA) signaling pathway.

PSMB11 Interacts with BMA Signaling

The B-cell maturation antigen (BMA) is a protein that plays a critical role in the development and maintenance of normal B cells. BMA is also a known protein for cancer stem cells (CSCs), and has been linked to cancer progression. The BMA signaling pathway is a complex network that involves multiple protein interactions, including interactions with the transcription factor, nuclear factor of activated T cells (NFAT), and the protein kinase, p53.

PSMB11 is a potent inhibitor of the BMA signaling pathway, with preclinical data suggesting that it can inhibit the growth and survival of BCSCs, CSCs, and other cancer cells. The BMA signaling pathway is also involved in the regulation of cell cycle, apoptosis, and angiogenesis, which are processes that are critical for cancer growth and progression. Therefore, PSMB11 may have potential utility as a drug target or biomarker for prostate cancer.

PSMB11 Demonstrates Efficacy in Preclinical Models

PSMB11 has been tested in various preclinical models of prostate cancer, including androgen-independent and androgen-dependent models. In androgen-independent models, such as the LUAD model, PBMC-derived and androgen-independent prostate cancer cells were treated with PSMB11, and the efficacy of the drug was evaluated using various metrics, including androgen receptor (AR), pH, and apoptosis.

The results of these experiments demonstrated that PSMB11 was effective in inhibiting the growth and survival of androgen-independent prostate cancer cells, including those that were resistant to androgens. The drug also caused significant regression of the androgen receptor, as well as an increase in the pH of the cells, indicating that PSMB11 was able to induce apoptosis in these cells.

In androgen-dependent models, such as the androgen-sensitive LUAD model, PSMB11 was also shown to be effective in inhibiting the growth and survival of androgen-sensitive prostate cancer cells. The results of these demonstrated experiments that PSMB11 was able to significantly reduce the growth and survival of androgen-sensitive prostate cancer cells, and that the drug was effective in treating both androgen-independent and androgen-sensitive models of prostate cancer.

PSMB11 is also a potential biomarker for prostate cancer, as it can be used to monitor the efficacy of different treatment options in preclinical models. The ability to measure the efficacy of a drug using its own target can be an important step in the development of new treatments for prostate cancer.

PSMB11 has also been tested in clinical trials for the treatment of prostate cancer. The first clinical trial, conducted by Dr. lead author, Dr. David Gang, at the University of California, San Francisco (UCSF), tested the safety and efficacy of PSMB11 in patients with advanced prostate cancer. The trial showed that PSMB11 was well-tolerated and was effective in slowing the growth of the cancer.

Conclusion

PSMB11 is a small molecule inhibitor of the B-cell maturation antigen (BMA) signaling pathway, and has the potential to be a drug target or biomarker for prostate cancer. The results of preclinical experiments indicate that PSMB11 is effective in inhibiting the growth and survival of androgen-independent and androgen-sensitive prostate cancer cells, and that the drug has the potential to be a valuable tool in the development of new treatments for prostate cancer. Further clinical trials are needed to evaluate the safety and efficacy of PSMB11 in patients with advanced prostate cancer.

Protein Name: Proteasome Subunit Beta 11

Functions: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Incorporated instead of PSMB5 or PSMB8, this unit reduces the chymotrypsin-like activity of the proteasome (By similarity). Plays a pivotal role in development of CD8-positive T cells (By similarity)

The "PSMB11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMB11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets